| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 464,450 | 801,282 | 613,077 | 510,598 |
| Short-term investments | 188,739 | 138,368 | 237,916 | 289,541 |
| Accounts receivable, net | 394,817 | 398,233 | 395,739 | 527,295 |
| Inventory | 1,001,112 | 914,744 | 1,077,166 | 994,036 |
| Manufacturing-related deposits and prepaids | 72,785 | 113,455 | 206,062 | 207,921 |
| Other current assets | 187,973 | 171,856 | 192,349 | 127,594 |
| Total current assets | 2,309,876 | 2,537,938 | 2,722,309 | 2,656,985 |
| Property and equipment, gross | NaN | 626,040 | NaN | NaN |
| Less accumulated depreciation | NaN | 280,472 | NaN | NaN |
| Less accumulated impairment loss | NaN | 443 | NaN | NaN |
| Property and equipment, net | 336,241 | 345,125 | 358,936 | 371,857 |
| Right of use assets | 124,059 | 125,495 | 139,167 | 143,041 |
| Non-current inventory | 174,865 | 184,543 | 198,601 | 194,668 |
| Non-current investments | 81,936 | 1,048 | 1,040 | 34,604 |
| Strategic investments | NaN | NaN | NaN | 195,522 |
| Other non-current assets | 151,957 | 155,554 | 73,384 | 83,137 |
| Total assets | 3,178,934 | 3,349,703 | 3,493,437 | 3,679,814 |
| Accounts payable | 70,376 | 280,841 | 94,015 | 136,702 |
| Accrued expenses | 302,372 | 359,659 | 295,793 | 377,399 |
| Deferred revenue, current portion | 116,037 | 443,397 | 485,449 | 395,431 |
| Contingent consideration, current portion | NaN | NaN | 36,000 | NaN |
| Other current liabilities | 10,379 | 11,393 | 10,168 | 10,416 |
| Total current liabilities | 499,164 | 1,095,290 | 921,425 | 919,948 |
| Long-term debt | 838,162 | 828,974 | 1,035,146 | 1,139,458 |
| Lease liabilities, net of current portion | 198,505 | 199,378 | 215,042 | 214,419 |
| Deferred revenue, net of current portion | 136,354 | 83,910 | 0 | 0 |
| Contingent consideration | NaN | 0 | 300 | 47,400 |
| Other non-current liabilities | 1,647 | 1,529 | 1,404 | 1,204 |
| Total liabilities | 1,673,832 | 2,209,081 | 2,173,317 | 2,322,429 |
| Common stock, 0.0001 par value, 198,000,000 shares authorized 98,254,898 and 96,900,496 issued and outstanding at march 31, 2025, and december 31, 2024, respectively | 11 | 11 | 11 | 10 |
| Treasury stock, at cost, 655,642 and 650,876 shares at march 31, 2026 and december 31, 2025, respectively | 25,263 | 25,263 | 25,263 | 25,263 |
| Additional paid-in capital | 6,076,500 | 6,042,586 | 5,986,689 | 5,844,279 |
| Accumulated other comprehensive income (loss), net of tax | -121 | 272 | 220 | -51 |
| Accumulated deficit | -4,546,025 | -4,876,984 | -4,641,537 | -4,461,590 |
| Total stockholders equity | 1,505,102 | 1,140,622 | 1,320,120 | 1,357,385 |
| Total liabilities and stockholders equity | 3,178,934 | 3,349,703 | 3,493,437 | 3,679,814 |
Sarepta Therapeutics, Inc. (SRPT)
Sarepta Therapeutics, Inc. (SRPT)